Dr Wei Chen
Executive Director, CMC Leader and Head of Global Device and Supply Chain,

About

Wei Chen, PhD, is Executive Director of Global Drug Product Operations and Chemistry, Manufacturing and Controls (CMC) leader at WuXi Biologics. Since joining the organisation in 2022, he provides strategic leadership for device technology assessment, design and development, engineering / characterisation, clinical and commercial manufacturing, assembly / packaging / labelling and regulatory filings.

His comprehensive oversight extends to CMC strategies and alliance management. Prior to his current role at WuXi Biologics, he held positions of increasing responsibilities at Protagonist, Gilead, Eli Lilly and Fresenius. Dr Chen received a PhD in Pharmaceutical Sciences from the University of Georgia (Athens, GA, US), and an MBA from Golden Gate University (San Francisco, CA, US).

Contributions

EXPERT VIEW

ANTIBODY-DRUG CONJUGATES: AN EMERGING FRONTIER IN IV TO SC CONVERSION

Dr Mehul Desai, Dr Michael Hageman and Dr Wei Chen examine the growing antibody-drug conjugate market, the unique formulation challenges these therapies present for subcutaneous delivery and how innovations in on-body injector technology may offer a practical path forwards.